ARS Pharmaceuticals, Inc. SPRY EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s EPS (diluted)?
- ARS Pharmaceuticals, Inc. (SPRY) reported EPS (diluted) of -$0.61 in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- ARS Pharmaceuticals, Inc.'s EPS (diluted) decreased by 74.3% year-over-year, from -$0.35 to -$0.61.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s EPS (diluted)?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s EPS (diluted) has grown at a 26.2% compound annual growth rate (CAGR), from -$0.87 to -$1.75.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.